These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1137 related items for PubMed ID: 18261327

  • 21. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads.
    Benveniste O, Flahault A, Rollot F, Elbim C, Estaquier J, Pédron B, Duval X, Dereuddre-Bosquet N, Clayette P, Sterkers G, Simon A, Ameisen JC, Leport C.
    J Infect Dis; 2005 May 15; 191(10):1670-9. PubMed ID: 15838794
    [Abstract] [Full Text] [Related]

  • 22. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
    Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS.
    AIDS; 2006 May 12; 20(8):1117-23. PubMed ID: 16691062
    [Abstract] [Full Text] [Related]

  • 23. CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort.
    Glencross DK, Janossy G, Coetzee LM, Lawrie D, Scott LE, Sanne I, McIntyre JA, Stevens W.
    Cytometry B Clin Cytom; 2008 May 12; 74 Suppl 1():S131-40. PubMed ID: 18228566
    [Abstract] [Full Text] [Related]

  • 24. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
    Li WJ, Dai Y, Han Y, Qiu ZF, Xie J, Zuo LY, Li YL, Li TS.
    Zhonghua Yi Xue Za Zhi; 2011 May 24; 91(19):1318-22. PubMed ID: 21756757
    [Abstract] [Full Text] [Related]

  • 25. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.
    Miró JM, Manzardo C, Pich J, Domingo P, Ferrer E, Arribas JR, Ribera E, Arrizabalaga J, Loncá M, Cruceta A, de Lazzari E, Fuster M, Podzamczer D, Plana M, Gatell JM, Advanz Study Group.
    AIDS Res Hum Retroviruses; 2010 Jul 24; 26(7):747-57. PubMed ID: 20624069
    [Abstract] [Full Text] [Related]

  • 26. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S, AIEDRP Network.
    J Infect Dis; 2006 Sep 15; 194(6):725-33. PubMed ID: 16941337
    [Abstract] [Full Text] [Related]

  • 27. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment.
    Kvale D, Ormaasen V, Kran AM, Johansson CC, Aukrust P, Aandahl EM, Frøland SS, Taskén K.
    AIDS; 2006 Apr 04; 20(6):813-20. PubMed ID: 16549964
    [Abstract] [Full Text] [Related]

  • 28. Cd38 expression on Cd8+ T cells in Human immunodeficiency virus 1-positive adults treated with HAART.
    Beran O, Holub M, Spála J, Kalanin J, Stanková M.
    Acta Virol; 2003 Apr 04; 47(2):121-4. PubMed ID: 14524479
    [Abstract] [Full Text] [Related]

  • 29. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
    Zhang ZN, Shang H, Jiang YJ, Liu J, Dai D, Diao YY, Geng WQ, Jin X, Wang YN.
    Chin Med J (Engl); 2006 Dec 05; 119(23):1966-71. PubMed ID: 17199940
    [Abstract] [Full Text] [Related]

  • 30. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A, Galli L, Torti C, D'Arminio Monforte A, Mussini C, Antinori A, Cozzi-Lepri A, Ladisa N, De Luca A, Seminari E, Gianotti N, Lazzarin A.
    Antivir Ther; 2010 Dec 05; 15(2):165-75. PubMed ID: 20386071
    [Abstract] [Full Text] [Related]

  • 31. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W.
    J Clin Virol; 2008 Apr 05; 41(4):310-3. PubMed ID: 18316243
    [Abstract] [Full Text] [Related]

  • 32. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
    de Mendoza C, Soriano V, Pérez-Olmeda M, Rodés B, Casas E, González-Lahoz J.
    J Hum Virol; 1999 Apr 05; 2(6):344-9. PubMed ID: 10774551
    [Abstract] [Full Text] [Related]

  • 33. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR, Kumar A, Sippy N, Carter AO, Roach TC.
    HIV Med; 2006 Mar 05; 7(2):99-104. PubMed ID: 16420254
    [Abstract] [Full Text] [Related]

  • 34. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
    Raffi F, Reliquet V, Francois C, Garre M, Hascoet C, Allavena C, Arvieux C, Breux JP, Perre P, Rozenbaum W, Auger S.
    Antivir Ther; 1998 Mar 05; 3 Suppl 4():57-60. PubMed ID: 10723512
    [Abstract] [Full Text] [Related]

  • 35. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M, Swiss HIV Cohort Study Group.
    Arch Intern Med; 2003 Oct 13; 163(18):2187-95. PubMed ID: 14557216
    [Abstract] [Full Text] [Related]

  • 36. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
    Nemes E, Lugli E, Nasi M, Ferraresi R, Pinti M, Bugarini R, Borghi V, Prati F, Esposito R, Cossarizza A, Mussini C.
    AIDS; 2006 Oct 24; 20(16):2021-32. PubMed ID: 17053348
    [Abstract] [Full Text] [Related]

  • 37. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.
    Bisson GP, Gross R, Strom JB, Rollins C, Bellamy S, Weinstein R, Friedman H, Dickinson D, Frank I, Strom BL, Gaolathe T, Ndwapi N.
    AIDS; 2006 Aug 01; 20(12):1613-9. PubMed ID: 16868442
    [Abstract] [Full Text] [Related]

  • 38. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group.
    Clin Infect Dis; 2007 Aug 01; 45(3):381-90. PubMed ID: 17599319
    [Abstract] [Full Text] [Related]

  • 39. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B, Swiss HIV Cohort Study.
    Arch Intern Med; 2003 May 26; 163(10):1220-6. PubMed ID: 12767960
    [Abstract] [Full Text] [Related]

  • 40. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study.
    Clin Infect Dis; 2005 Aug 01; 41(3):361-72. PubMed ID: 16007534
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.